Significantly more non-small cell lung cancer (NSCLC) patients receiving Opdivo and chemotherapy before surgery showed no evidence of cancer cells in their resected tissue, the company said.
The combination of Britol's Opdivo and Yervoy is already approved for treating patients with non-small cell lung cancer.
Bristol said the trial is ongoing to assess the other main goal of evaluating the length of time after primary treatment that the patient remains free of complications.
Non-small cell lung cancer accounts for about 85% of lung cancer cases, making it a lucrative market, which is currently dominated by Merck & Co's rival drug Keytruda.
Opdivo spurs the immune system to fight cancer and is one of Bristol's top-selling drugs.
By Reuters Staff
Posted on
Previous Article
« Solriamfetol effective for treating excessive daytime sleepiness Next Article
Study helps gauge long-term risks for women with DCIS by treatment »
« Solriamfetol effective for treating excessive daytime sleepiness Next Article
Study helps gauge long-term risks for women with DCIS by treatment »
Related Articles
November 26, 2019
First-line osimertinib significantly lengthens OS in NSCLC
September 21, 2021
New preoperative classification scheme proposed for oligometastatic NSCLC
September 21, 2021
Pembrolizumab shows potential in TKI-resistant EGFR+ NSCLC, not ALK+
© 2023 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy